Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B‐cell lymphoma: Current state of the art and unmet clinical needs

Kenneth Ofori,Govind Bhagat,Alex J. Rai

DOI: https://doi.org/10.1111/bcp.14611

2020-11-18

British Journal of Clinical Pharmacology

Abstract:<p>Diffuse large B‐cell lymphoma (DLBCL) is the most common type of non‐Hodgkin's lymphoma, constituting biologically heterogeneous entities. Standard first line therapies cure ~60% of patients, the rest being either refractory or experiencing relapse. Currently, there are no robust predictive biomarkers of therapeutic response. Heterogeneity of DLBCL is partly explained by the cell of origin (COO), i.e. germinal center B cell (GCB) or activated B cell (ABC), with the latter exhibiting worse prognosis. While gene expression profiling (GEP) is the gold standard for determining COO, surrogate immunohistochemical algorithms are used clinically, but show significant discordance with GEP. Recently, additional subgroups with different prognoses have been reported. However, the tools/expertise required for analysis prohibit widespread deployment. Liquid biopsy‐based assays show promise in providing clinically actionable information, are non‐invasive and facilitate serial sampling to assess mechanisms of therapy resistance. Circulating, cell free DNA analysis has shown enhanced sensitivity, however, this modality cannot provide information on signaling pathways. Exosomes are endosomally derived vesicles, are found in high abundance in body fluids, and readily isolated using a variety of methods. Tumor derived exosomes contain genetic information and can reveal details for diagnostic, prognostic and therapeutic purposes in DLBCL. At present, standardized techniques for isolating exosomes are lacking and discriminating exosomes from neoplastic or normal B cells is challenging. Refinements in isolation procedures are required to realize their full potential as precision medicine tools to provide comprehensive information on disease subtypes, identify prognostic factors, allow real time monitoring of therapy response and to delineate drug targets.</p>

pharmacology & pharmacy